New Drugs for Juvenile Myositis Virtual Symposium

preview_player
Показать описание
Cure JM Foundation and Duke University Cure JM Center of Excellence proudly present a virtual symposium featuring speakers from pharma, biotech, research hospitals and the NIH.

Symposium focus:
New drugs for Juvenile Myositis (JM), including drugs that are actively being repurposed from other indications and new drugs that are not yet registered for any disease.

Sessions cover:
An overview of the biology, genomics and genetics associated with JM, highlighting potential pathways that could be targeted for therapeutic intervention. A range of drugs that are in clinical trials or planned to enter clinical trials in JM patients, discussing their target pathway and potential in treating JM patients.

Featuring: session chairs Robert A. Colbert, MD, PhD, Clinical Director and Chief of Pediatric Translational Research Branch, NIAMS/NIH and Ann M. Reed, MD, Chair, Department of Pediatrics, Duke University School of Medicine.
AGENDA WITH TIMECODES
0:00:00 Opening comments and introduction. Andrew Heaton, PhD (CSO, Cure JM Foundation)
0:09:23 Introduction to biology and potential druggable targeting JM treatment. Jeffrey Dvergsten, MD (Duke University, Duke Children’s Health Center)
0:38:42 Introduction to the JAK/STAT pathway, a key druggable target for the treatment of JM. John O’Shea, MD (NIAMS/NIH)
1:03:25 Baricitinib in refractory JM patients. Hanna Kim, MD, MS (NIAMS/NIH)
1:29:39 SOCS1 mimetic peptide as novel JAK inhibitor for potential treatment of JM. Charlly Kao, PhD (Center for Applied Genomics, Children’s Hospital of Philadelphia)
1:58:45 Calcinosis in JM, its treatment and the use of sodium thiosulfate in its management. Adam Schiffenbauer, MD (NIEHS/NIH)
2:25:54 Development of vamorolone as a less toxic anti-inflammatory steroid. Eric Hoffman, PhD (VP of Research, ReveraGen)
2:46:54 Abataceptin refractory JM. Rodolfo Curiel, MD, FACP, FACR (Medical Faculty Associates, The George Washington University)
3:11:39 The biology of ECS and CB2 agonism as a potential target for DM and other autoimmune diseases. Quin Dinh, MD (VP Head of Medical Affairs, Corbus Pharmaceuticals)
3:34:14 Closing remarks. Kaveh Ardalan, MD (Duke University, Duke Children’s Health Center)
Рекомендации по теме